市場調查報告書
商品編碼
704728

狂犬病(恐水症)疫苗的全球市場:成長,趨勢,及預測

Rabies Vaccine Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 114 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球狂犬病(恐水症)疫苗市場的相關調查,市場機會和課題,成長及阻礙因素,各產品類型、疫苗類型、終端用戶、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的假設
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各產品類型
  • 各疫苗接種類型
    • 暴露前疫苗接種類(PEV)
    • 暴露後疫苗接種類(PEP)
  • 各終端用戶
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲地區
    • 南美

第6章 競爭情形

  • 企業簡介
    • AstraZeneca (MedImmune)
    • Berna Biotech Ltd
    • GlaxoSmithKline
    • Merck & Co Inc
    • Novartis AG
    • Pfizer Inc
    • Sanofi Pasteur, Inc
    • Zoetis Animal Healthcare
    • *清單為例示列舉。

第7章 市場機會及未來趨勢

目錄
Product Code: 62883

The Rabies Vaccine Market was estimated to be to grow at a CAGR of 5.0% during the forecast period of 2021-2026. The COVID-19 pandemic is expected to have a significant impact on the market. In April 2020, the Food Agriculture Organization published a new policy regarding the production of livestock and supply chain of livestock products during the COVID-19 pandemic. As per the data of the Centers for Disease Control and Prevention (CDC) in 2020, cats, dogs, and a few other types of animals are at potential risk of acquiring this virus. The virus was recently detected in mink in multiple farms of the Netherlands in 2020. Several studies are being undertaken to understand the connection between animals and the human transmission of this virus. Additionally, in October 2020, a study was published in the Nature magazine titled, 'Rabies virus-based COVID-19 vaccine CORAVAX induces high levels of neutralizing antibodies against SARS-CoV-2', that studied the rapid development of a novel, highly efficient, and safe COVID-19 vaccine using a rabies virus-based vector that has proven to be an efficient vaccine against several emerging infectious diseases. These developments are expected to boost market growth.

Rabies is a viral infection which can be prevented by vaccination. It occurs in more than 150 countries across the world. Dogs are the primary cause of human rabies mortality, causing up to 99% of all human rabies transmissionaccording to the World Health Organization (WHO) in May 2021. As per the same source, more than 29 million people around the world seek post-bite vaccine every year, whereas 40% of individuals infected by alleged rabies are infants under 15 years of age. Rabies is prevalent on all continents, except Antarctica, with more than 95% of human mortality reported in the Asian and African regions. According to the WHO, rabies kills nearly 59,000 people every year, worldwide. Evidence also shows that the prevention of dog rabies by animal vaccination programs and removal of stray dogs are likely to reduce rabies infection, but still dog rabies continues to remain prevalent in several countries and exposure to rabies is still the cause of more than 90% of human rabies infection and 99% of human deaths due to rabies, worldwide. The Association of Southeast Asian Nations (ASEAN) had initially adopted a national elimination plan to eradicate human rabies in the region by the end of 2020, although their success has been limited in some areas. Thus, considering the rising burden of mortality owing to the increasing cases of rabies around the world specially in low income economies, the market is expected to show a stable growth during the forecast period.

Key Market Trends

The Purified Chick Embryo Cell Rabies Vaccine is Expected to Show Better Growth

The purified chick embryo cell vaccine is used to protect people from post-exposure or pre-exposure. The veterinarians who are in contact with animals, such as cats, dogs, foxes, skunks, raccoons, bobcats, coyotes, and bats are more likely to be exposed to the rabies virus, leading to rising cases of rabies. Purified chick embryo cell rabies vaccines are prepared with the help of primary chick embryo cells derived from specific pathogen-free (SPF) eggs. It consists of purified and concentrated rabies virus antigen, inactivated with B-propiolactone. This vaccine acts by exposing a small dose of rabies virus to the patient in order to develop immunity to the disease. There are some side effects, such as very high fever, tingling or prickly feeling in fingers or toes, weakness or unusual feeling in arms and legs, problems with balance or eye movement, and trouble while speaking or swallowing.

The rise in incidences of animal bites and rising government initiatives are expected to propel the growth of the market studied over the forecast period. This vaccine can be used for post-exposure or pre-exposure. Such factors drive its importance and usage across hospitals and clinics.

North America is Estimated to Have Largest Share in the Global Market

The United States is the largest market in the North American region. According to the data published by Centers for Disease Control and Prevention (CDC) in the United States, wild animals accounted for 92.7% of the rabies cases, whereas domestic animals accounted for 48.2% of cases of rabies in 2018. Nearly 5,000 cases of animal rabies are reported yearly to the CDC, and more than 90% of such cases occur in wildlife. This reflects a drastic shift in the types of animals identified as feral since 1960, when the bulk of cases occurred in domestic animal species, mainly dogs. In the past few years, the number of human deaths attributed to rabies in the United States had declined due to two major reasons - animal control and vaccination programs. Furthermore, effective human rabies vaccines and immunoglobulins have also been developed over time. Additionally, the US government is also taking several initiatives to reduce the cases of rabies. United Against Rabies, a collaboration of four partners consisting of World Health Organization (WHO), Food and Agriculture Organization of the United Nations (FAO), World Organization for Animal Health (OIE), and Global Alliance for Rabies Control (GARC) developed a global strategic plan to achieve zero rabies human deaths by 2030.

Thus, the rise in the development of effective human rabies vaccines and immunoglobulins, and the increasing government initiatives are expected to boost the market's growth over the forecast period.

Competitive Landscape

The major market players are focusing on technological advancements and pet care initiatives in collaboration with hospitals and government channels. Some of the major players in the market are Zoetis Inc., Merck & Co Inc, Sanofi SA, Elanco, and Virbac.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Mortality due to Rabies
    • 4.2.2 Large Population of Stray Dogs in Low and Middle Income Countries
    • 4.2.3 Growing Pet Management technological Advancements and Services
  • 4.3 Market Restraints
    • 4.3.1 Low Immunization Rates in Dogs
    • 4.3.2 Lack of Awareness and Negligence by Government and Public
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Baby Hamster Kidney (BHK)
    • 5.1.2 Purified Chick Embryo Cell Rabies Vaccine
    • 5.1.3 Vero Cell Rabies Vaccine
    • 5.1.4 Other Product Types
  • 5.2 By Vaccination Type
    • 5.2.1 Pre-Exposure Vaccination (PEV)
    • 5.2.2 Post-Exposure Prophylaxis (PEP)
  • 5.3 By End-User
    • 5.3.1 Animals
    • 5.3.2 Humans
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Berna Biotech Ltd
    • 6.1.2 GlaxoSmithKline plc
    • 6.1.3 Merck & Co Inc
    • 6.1.4 Novartis AG
    • 6.1.5 Pfizer Inc
    • 6.1.6 Sanofi SA
    • 6.1.7 Zoetis Inc.
    • 6.1.8 Elanco
    • 6.1.9 Virbac
    • 6.1.10 Boehringer Ingelheim International GmbH
    • 6.1.11 Bharat Biotech

7 MARKET OPPORTUNITIES AND FUTURE TRENDS